くすりのしおり

Injection
Revised: 11/2020

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
GRAN SYRINGE 150 [for mobilization of hematopoietic progenitor cells into peripheral blood (autologous peripheral blood progenitor cell collection)]
 Active ingredient:
Filgrastim(genetical recombination)
 Dosage form:
injection
 Print on wrapping:

Effects of this medicine

This medicine works for mobilization (release) of hematopoietic progenitor cells from bone marrow to blood.
It is usually used for mobilization of hematopoietic progenitor cells into peripheral blood.

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
    If you have previously experienced rash or itch after administrating any other medicines which increase leukocytes (neutrophils).
    If you have myeloid leukemia (incl. myelodysplastic syndrome) with insufficient decrease of leukemic cells in the bone marrow or presence of leukemic cells in the blood.
    If you are scheduled to be administered or have been administered an anticancer agent within 24 hours.
  • If you are pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • In general, this medicine is administered subcutaneously daily, at one time or in two divided doses.
  • Duration of administration will be determined by monitoring the effects. Ask your doctor about the duration of administration.
  • You may be administered lower dose of this medicine intradermally to check if there are any unwanted responses.

Precautions while taking this medicine

  • This medicine may cause splenomegaly or splenic rupture. Be aware of change in your blood data and receive close observation such as receiving abdominal ultrasound examination.

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include bone pain, lumber pain and fever. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
  • hives, breathing difficulty, dizziness [shock, anaphylaxis]
  • shortness of breath, cough, fever [interstitial pneumonia]
  • breathing difficulty, rapid breathing, nails and lips turning blueish purple [acute respiratory distress syndrome]
  • upper left abdominal discomfort, upper left abdominal pain [splenomegaly, splenic rupture]
  • shortness of breath, fever, general malaise, easy to bleed, dizziness  [increase in myeloblasts]
  • general edema, rapid weight gain, increased heart rate [capillary leak syndrome]
  • fever, general malaise, pain in various parts such as the neck [large vessel vasculitis (inflammation of aorta, common carotid artery, subclavian artery, etc.)]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.